logo
+44 (0)1223 496557
info@cambridgeproteinarrays.com
Research and development of protein arrays and their applications in proteomics
home
Technology
HuProt arrays
Services
News & Events
Publications
About Us
Contact

image

image

6th Alpbach Workshop on Affinity Proteomics, 11-13 March 2013 

This meeting, organised by the Affinomics consortium, was the 6th in a series of workshops previously held in Cambridge 2004, Uppsala 2005 and Alpbach 2007, 2009 and 2011. The workshop reviewed methods for generation and quality control for binding reagents and applications in high-throughput proteomics.

 

Programme: The final programme is now available for download here.
 

Sponsors: Affinomics, European Science Foundation, Olink Bioscience, Alligator Bioscience, Cambridge Protein Arrays

           

Venue: The meeting was held in the Congress Centre in the alpine village of Alpbach in the Austrian Tyrol.

Speakers: Leigh Anderson (Washington DC), Carl Borrebaeck (Lund), Andrew Bradbury (Los Alamos), Stefan Dübel (Braunschweig), Larry Gold (Boulder), David Juncker (Montreal), Walter Kolch (Dublin), Tony Kossiakoff (Chicago), Ulf Landegren (Uppsala), Hanno Langen (Basel), Garry Nolan (Stanford), Andreas Plückthun (Zürich), Tom Soh (Santa Barbara), Marius Ueffing (Tübingen), Mathias Uhlén (Stockholm)
, Bernd Wollscheid (Zurich)
 

Main Organisers: Mike Taussig and Cheryl Smythe

 

Background: Antibodies and other affinity binders are among the most powerful analytical tools for life sciences research, diagnostics and increasingly therapeutics for cancer and autoimmune disease. Affinity proteomics seeks to use them to analyse proteomes using collections of specific binding reagents. While the most familiar affinity reagents are the classical antibodies and their fragments, there are also alternative engineered forms of novel protein scaffolds and nucleic acid aptamers with similar diversity and binding properties. A binder collection must be accompanied by development of high-throughput assay systems and look towards applications in functional analysis, diagnostics and therapeutics. Results achieved through affinity proteomics technologies will have a strong impact on the biomedical, pharmaceutical and biotech industries.